Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07785830 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07785830 · ClinicalTrials.gov record · last posted 2026-08-25

A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007)

StatusNot Yet Recruiting
PhasePhase 1
Started2026-09-25
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Researchers are looking for new treatments for people living with HIV-1 (Human Immunodeficiency Virus Type 1). HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. MK-4646 is a trial medicine designed to treat HIV-1. Before giving a trial medicine to people with a health condition, researchers first do studies in healthy participants. The goals of this trial are to learn: * What happens to rosuvastatin in a participant's body over time when it is taken with MK-4646 * About the safety of MK-4646 when taken with rosuvastatin and if people tolerate it. Tolerate means participants will receive trial medicine in the trial unless they need to stop it due to health problems.
Trial Details
NCT Number NCT07785830
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 16 participants
Start Date 2026-09-25
Primary Completion 2026-11-10 (estimated)
Study Completion 2026-11-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-25